Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill. Here's why they think ...

Dividend growth stocks have long been reliable engines of wealth creation. Historically, companies with 10-year annualized ...

Abbott Laboratories is a dividend stock you ... stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons.

Humira is a treatment for moderate to severe rheumatoid arthritis, the first of six disease indications it has received en route to becoming Abbott's most successful product ever. Abbott acquired ...

Abbott Laboratories has been paying a dividend ... a matter of time before key patents for its autoimmune disease drug Humira would expire. The company was heavily dependent on Humira's sales.

Once reliant on Humira for revenue ... The critical takeaway is that it, like its parent, Abbott Laboratories, is a healthy capital-returning machine on track to pay substantial dividends while ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, ...